ClinicalTrials.gg
RecruitingNCT06907095LEAHUpdated Mar 30, 2026

Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals

An interventional study of biological samples in Risk of Breast Cancer, Risk of Gynaecological Cancer and Risk of Colorectal Cancer, sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Gustave Roussy, Cancer Campus, Grand Paris · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5,909
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 236 studies in Head and Neck Neoplasms with a site in France — 49 open to participants now, 69 under way, 11 of them phase 3. Head and Neck Neoplasms · France.

Planned enrollment
Largest of 197
5,909 · median 110
Started
2026
with 7 others
No phase
63 of 236
22 open now
Primary completion
2030-06
later than 64 of 68 live
Registered
228th of 236
by date
Lead sponsor
7 of 236
Gustave Roussy, Cancer Campus, Grand Paris

Among the 236 studies in Head and Neck Neoplasms with a site in France, this one has the largest planned enrollment of the 197 interventional ones that give a count, is one of 8 that started in 2026, is one of 63 with no phase, reaches primary completion later than 64 of the 68 other live ones, and was the 228th registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

49 of the 236 studies in Head and Neck Neoplasms with a site in France are open now. Recruiting first, the newest first:

43 more — sign in →

All 49 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Head and Neck Neoplasms with a site in France, or all of them as a file.
02

Study summary

LEAH is a prospective, observational, single-centre, non-randomised, open-label study of people at increased risk of cancer or malignant disease.

The main objective of LEAH is to evaluate and compare the sensitivity of different tests on body fluids to detect cancers that will occur within 3 years of inclusion in the study, in a cohort of individuals identified as being at increased risk of cancer.

03

Conditions studied

  • Risk of Breast Cancer
  • Risk of Gynaecological Cancer
  • Risk of Colorectal Cancer
  • Risk of Upper Gastrointestinal Cancers
  • Risk of Hepatic Cancers
  • Risk of Lung Cancer
  • Risk of Skin Cancers Except Basal-cell Carcinomas
  • Risk of Head and Neck Cancers
  • Risk of Mesothelioma
  • Risk of Kidney Cancer
  • Risk of Prostate Cancer
  • Risk of Urothelial Cancers
  • Risk of Endocrine Cancers
  • Risk of Hematologic Malignancies
  • Risk of Several Cancer Types
  • Risk of Second Malignancy in Individuals Treated for a Childhood Cancer
  • Risk of Neoplasia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria increased risk cohort:

  1. Are aged 18 or more
  2. Have a cumulative 3-year risk of developing any cancer ≥ 4% (including the situation specific cancers + other cancers) defined as follows:

    1. Situations at increased risk of breast cancer

      • Women carrying germline pathogenic (P) or likely pathogenic (LP) variants of BRCA1, BRCA2, TP53, PALB2, PTEN, CDH1 genes without prophylactic mastectomy, aged ≥ 40 years, or
      • Men with germline (P) or (LP) variants in the BRCA2 gene, aged ≥ 40 years, or
      • Women with a personal history of an histological atypical breast lesion in the past 5 years and aged ≥ 50 years, or
      • Women with a personal history of unilateral breast cancer (including ductal carcinoma in situ) diagnosed more than 5 years before inclusion, and currently aged ≥ 60 years, or
      • Women who received chest radiotherapy before age 30 years and currently aged ≥ 25 years, or
      • Women with an invasive breast cancer risk > 2.5% over the next 5 years, as defined by risk scores +/- genotyping, and aged ≥ 50 years, or
      • Individuals identified at increased risk in MyPeBS trial (> 2.5% over the next five years) (www.mypebs.eu) can be eligible for the study, if aged ≥ 50 years, or
    2. Situations at increased risk of gynaecological cancer

      • Women with a Lynch syndrome - germline (P) or (LP) variants in hMLH1, MSH2, hMLH6, PMS2, and aged ≥ 30 years, or
      • Women carrying germline (P) or (LP) variants of BRCA1, BRCA2, PALB2, RAD51C or RAD51D, PTEN genes without prophylactic oophorectomy, aged ≥ 40 years, or POLE and POLD1, and aged > 30 years; or SMARCA4 or DICER1 and aged > 18 years or
    3. Situations at increased risk of colorectal cancer

      • Men or women with a Lynch syndrome - germline (P) or (LP) variants in hMLH1, MSH2, hMLH6, PMS2, APC, POLE, POLD1, BMPR1A, SMAD4 or biallelic MuTYH genes, and aged ≥ 40 years, or
      • Individuals with an increased risk of colorectal cancer defined by the following criteria and aged ≥ 50 years, or
      • First-degree relative diagnosed with colorectal cancer before the age of 60 years, or
      • Two or more 1st degree relatives diagnosed with colorectal cancers at any age, or
      • Personal history of any colorectal adenoma before the age of 50 years or adenomatous polyps > 1 cm, villous adenomas, dysplastic adenomas, or ≥ 3 adenomatous polyps after the age of 50 years, or
      • Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis) after the age of 50 years, or
    4. Situations at increased risk of upper gastrointestinal cancers

      • Carriers of an STK11 or CDH1 germline (P) or (LP) variants and aged > 30, or
      • Individuals with an increased risk of esophageal adenocarcinoma: Barrett's esophagus with high-grade dysplasia, or
    5. Situations at increased risk of hepatic cancers

      - Individuals at increased risk of hepatocellular carcinoma because of documented liver fibrosis or cirrhosis (whether secondary to non-alcoholic steatohepatitis, alcohol-related, or virus-related), or

    6. Situations at increased risk for pancreatic cancers

      • Patients with a family history with > 2 pancreatic cancers in close relatives and aged >50 or
      • Chronic pancreatitis and aged >50 or carriers of PRSS1 or SPINK1 germline (P) or (LP) variants or
      • Patients at increased risk of pancreatic cancer based on a composite score or
      • Carriers of CDKN2A germline (P) or (LP) variants or
      • Carriers of germine (P) or (LP) variants in BRCA2, ATM, BRCA1, PALB2, or Lynch syndrome-associated gene alterations with a first-degree or multiple family history of pancreatic ductal carcinoma (PDAC) or
      • Patients with a Peutz-Jeghers syndrome (STK11 germline (P) or (LP) variants) or
    7. Situations at increased risk of lung cancer

      - History of heavy smoking > 20 pack-years among active or previous smokers who have quitted up to 10 years ago, and aged ≥ 50 years, or

    8. Situations at increased risk of skin cancers except basal-cell carcinomas

      • Carriers of germline (P) or (LP) variants in CDKN2A/CDK4 or BAP1 genes, aged ≥ 50 years or
      • Carriers of germline (P) or (LP) variants of genes that predispose to skin cancers (Xeroderma pigmentosum, etc…) or
    9. Situations at increased risk of head and neck cancers

      • Individuals with high-grade dysplasia or carcinoma in situ of the upper aero digestive tract within the last 10 years, and aged ≥ 50 years, or
      • Individuals with oral lichen planus diagnosed more than 10 years ago, and aged ≥ 50 years or
      • Previous history of a head and neck cancer in complete remission for ≥ 5 years, aged ≥ 50 years, and at least one of the following criteria:

      Current or former smoker > 10 pack-years Current or former alcohol consumption > 14 units/week

    10. Situations at increased risk of mesothelioma

      - Individuals with a history of relevant professional exposure to asbestos, and/or germline (P) or (LP) variants in BAP1, and aged ≥ 50 years, or

    11. Situations at increased risk of kidney cancer

      - Carriers of germline (P) or (LP) variants in the BAP1, VHL, FH, cMET, FLCN, SDH-B genes, and aged ≥ 50 years, or

    12. Situations at increased risk of prostate cancer

      • Men aged ≥ 40 year with any of the following:
      • Strong family history: a first- or second-degree relative with prostate cancer, ovarian cancer, male breast cancer, female breast cancer aged ≤ 45 years, colorectal or endometrial cancer aged ≤ 50 years, pancreatic cancer or two or more first- or second-degree relatives with breast, prostate (but not clinically localized grade group 1), colorectal or endometrial cancer at any age, or
      • Carriers of germline (P) or (LP) variants in BRCA1, BRCA2, ATM, HOXB13, hMLH1, MSH2, hMLH6, and PMS2, and aged > 45
    13. Situations at increased risk of urothelial cancers

      • History of heavy smoking > 30 pack-years, among active or previous smokers who have quitted up to 10 years ago, and aged ≥ 50 years, or
      • Lynch syndrome with a germline (P) or (LP) variants in hMLH1, MSH2, hMLH6, PMS2, and aged ≥ 40 years, or
    14. Situations at increased risk of endocrine cancers

      • Increased risk of pheochromocytoma paraganglioma in individuals with germline (P) or (LP) variants in RET, VHL, SDHB, SDHD, and aged ≥ 35 years, or
      • Multiple endocrine neoplasia syndrome in individuals with germline (P) or (LP) variants in RET or MEN1, and aged ≥ 40 years, or
    15. Situations at increased risk of hematologic

      • Individuals aged ≥ 50 years with any of the following:
      • Clonal hematopoiesis of indeterminate potential, or
      • Aplastic anemia, or
      • Predisposing genetic alterations (P) or (LP) variants in GATA2, RUNX1, ANKRD26, ETV6, TP53, CEBPA, or DDX41 genes, or copy number variation of chromosome 14q32 region (CNVdup14), or
      • Patients who received high doses of platinum or other compounds who are estimated to have a > 2% risk of secondary hematological malignancies at 3 years, or
    16. Situations at increased risk of several cancer types

      • Germline deleterious mutations of TP53 (Li-Fraumeni syndrome), and aged > 18 or
      • Germline deleterious (P) or (LP) variants in PTEN, Cowden syndrome, and other PTEN-opathies, aged ≥ 30 years, or
      • Personal history of allogenic organ transplantation at least five years before the inclusion, with long-term ongoing treatment, and aged ≥ 50 years, or
      • Chronic carriers aged > 50, or
    17. Situations at increased risk of second malignancy in individuals treated for a childhood cancer

      • Brain radiation therapy during childhood, and aged ≥ 18 years, or
      • Childhood malignancy which required chemotherapy and/or radiation therapy, and aged ≥ 40 years, or
  3. Beyond the situations described previously, the following individuals are also eligible for LEAH:

    1. Increased risk of neoplasia linked to an underlying professional exposure, with a specific cancer risk estimated to be at least 2 % at 3 years, and aged ≥ 50 years, or
    2. Other situation: Any particular situation with accumulation of several risk factors likely to induce cancer with a specific risk of cancer estimated at least 2% at 3 years.
  4. Participants with a personal cancer or hematological malignancy history are allowed if they are in complete remission at least 5 years from the primary diagnosis
  5. All participants must understand spoken and written French language,
  6. All participants must agree to comply with the protocol requirements,
  7. All participants must understand, sign, and date the written form prior to any protocol-specific procedures performed.
  8. All participants must be able to access internet through their telephone or a computer

Inclusion criteria, control group

  1. Individuals seen for a rapid diagnostic procedure at the center as part of the Instadiag programme, that led to a diagnosis of a benign condition
  2. Who do not have a high risk situation as defined previously
  3. Agree to participate
  4. Aged >18
  5. They must understand spoken and written French language,
  6. They must agree to comply with the protocol requirements,
  7. They must understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed.
  8. They must be able to access internet through their telephone or a computer

Exclusion Criteria:

  1. Known prior diagnosis of cancer or hematological malignancy within the past 5 years except for non-melanoma skin cancers, in situ cervical cancers and for patients with germline TP53 alterations,
  2. Presence of signs or symptoms of cancer at enrolment,
  3. Acute exacerbation of an condition requiring escalation in medical therapy within 14 days prior to enrolment,
  4. Any medical condition with a high likelihood of mortality within three years,
  5. Physical or psychological conditions considered not to be compatible with the study and not likely to comply with follow up requirements,
  6. Individuals under guardianship or deprived of their liberty by a judicial or administrative decision or incapable of giving their consent,
  7. Women carriers of (P) or (LP) variants in BRCA1, BRCA2, PALB2, gene considering prophylactic mastectomy in a near future or aged less than 40 years (since their absolute risk of cancer is lower than the expected threshold)
  8. Received a blood transfusion within the last week before inclusion.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5,909 participants (estimated)

Study arms

  • Active comparator
    individuals at low risk of invasive cancer

    A cohort of individuals who are not considered at increased risk (low risk) of cancer seen in consultation for a problem defined as benign will also be recruited and be used for certain secondary and exploratory objectives.

    Diagnostic Test: biological samples

  • Active comparator
    individuals at high risk of invasive cancer

    Individuals with an estimated risk ≥ 4% of occurrence of any invasive cancer or malignancy (except for basal cell carcinoma of the skin) in the following three years after inclusion will be proposed the trial. This 4% cumulative risk represents the addition of i. the participant's general risk of any cancer or malignancy based on her/his age and ii. her/his risk of a specific malignancy based on her/his risk profile.

    Diagnostic Test: biological samples

Interventions

  • Diagnostic testbiological samples

    biological samples (blood, urine, saliva)

06

What researchers measure

Primary outcomes

  1. sensitivity of techniques derived from body fluids in the detection of any invasive cancer

    The primary endpoint is the sensitivity of body fluid-derived techniques in the detection of any invasive cancer (except for non-melanoma skin cancers) in the 36 months period following body fluid collection among individuals at increased risk of cancer.

    Time frame: baseline and In case of cancer within 3 years

Secondary outcomes

  1. Evaluation of the 3-year early detection performance of techniques derived from body fluids

    for different evaluation criteria: \< stage 2 cancer, any invasive cancer (SO.1, SO.2 and SO.3). These performances will be evaluated in individuals at increased risk of cancer and in subgroups of individuals with several cancer-specific risk situations, using standard performance indices (sensitivity, specificity, precision, negative/positive predictive value, accuracy, etc.) corrected for censoring.

    Time frame: baseline and In case of cancer within 3 years

  2. Evaluation in terms of predicting the risk of developing invasive cancer of the added value at 3 years of body fluid-derived techniques and their various combinations compared with standard baseline factors

    Time frame: baseline and In case of cancer within 3 years

  3. Assessment of the ability of body fluid-derived techniques to identify the tissue of origin by agreement between the location predicted by the body fluid-derived techniques and the tissue of origin.

    Time frame: baseline and In case of cancer within 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2030, 51 months after the start.

Of 440 non-industry interventional studies with no phase under Head and Neck Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 51 months is above that.

Counting every sponsor, half of 458 studies reached it within 33 months; a quarter within 18 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2025
First posted
Apr 2, 2025
StartActual
Mar 16, 2026
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2030
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06907095
Responsible party
Sponsor
First posted
Apr 2, 2025
Start date
Mar 16, 2026
Primary completion
Jun 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Mar 30, 2026

Study contacts

Suzette Delaloge, MD
Contact
suzette.delaloge@gustaveroussy.fr
+33 (0)1 42 11 42 11
Adeline Salasc, PharmD
Contact
adeline.salasc@gustaveroussy.fr
+33 (0)1 42 11 42 11
Suzette Delaloge, MD
study chair · Gustave Roussy, Veillejuif, France

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion